



## Supplementary Information




Figure S1. The HR-ESIMS data of 1.




Figure S2. The  $^1\text{H}$  NMR spectrum of **1** ( $\text{CD}_3\text{OD}$ , 800 MHz).





Figure S3. The  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of **1** ( $\text{CD}_3\text{OD}$ ).



**Figure S4.** The HSQC spectrum of **1** ( $\text{CD}_3\text{OD}$ ).






Figure S5. The HMBC spectrum of **1** ( $\text{CD}_3\text{OD}$ ).



**Figure S6.** The TOCSY spectrum of **1** (CD<sub>3</sub>OD).



**Figure S7.** The antiviral activity of compounds 1-8 against PR8, HRV1B, and CVB3 in vitro. In A549, Vero and Hela cells, the antiviral activity of compounds 1-8 were evaluated based on its effects on cell viability after infection with PR8 (A), HRV1B (B), CVB3 (C). Cell viability (%) was calculated based on results of the SRB assay.